VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 9, 2008) - Allon Therapeutics Inc. (TSX:NPC) announced today that it has been granted a United States patent covering composition, delivery and method of use for AL-309, the lead product candidate in the Company’s second neuroprotection technology platform, called Activity Dependent Neurotrophic Factor (ADNF).
